All In Biotech

Drug Trial Radar · NCT07002216

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage 2 B-IV Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jul 15, 2025

Primary completion

Jul 15, 2030

Study completion Jul 15, 2030

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.

Conditions

  • Hodgkin Lymphoma
  • Advanced Hodgkin Lymphoma

Interventions

  • Brentuximab VedotinDrug

    Participants will receive 1.8 mg/kg of Brentuximab Vedotin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

  • EtoposideDrug

    Participants will receive 150 mg/m\^2 of Etoposide intravenously (IV) for up to 60 minutes on Days 1-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

  • CyclophosphamideDrug

    Participants will receive 1250 mg/m\^2 of Cyclophosphamide intravenously (IV) for up to 60 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

  • DoxorubicinDrug

    Participants will receive 40 mg/m\^2 of Doxorubicin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

  • DacarbazineDrug

    Participants will receive 250 mg/m\^2 of Dacarbazine intravenously (IV) for up to 120 minutes on Days 2-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

  • DexamethasoneDrug

    Participants will self-administer 40 mg of Dexamethasone orally on Days 1-4 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.